Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 2Phase 2/3 1

Status

Active not recruiting 6Recruiting 1

Sponsor Class

INDUSTRY 4NIH 3

Study Type

Interventional 7

Sponsor

Cancer Type

Thoracic 28Gastrointestinal 12Genitourinary 7Gynecologic 5Tumor-Agnostic 4Breast 3Head & Neck 2Sarcoma 1

Conditions

Urinary Bladder Neoplasms 3Renal Pelvis and Ureter Urothelial Carcinoma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasm Metastasis 1Fallopian Tube Mucinous Adenocarcinoma 1Carcinoma, Renal Cell 1Carcinoma 1

Interventions

Magnetic Resonance Spectroscopy 46Specimen Handling 42Nivolumab 30pembrolizumab 29enzalutamide 28Gemcitabine 24Docetaxel 24apalutamide 20Prednisone 20Biopsy 19cabozantinib 17Abiraterone Acetate 17enfortumab vedotin 15Androgen Antagonists 15abiraterone 14Cisplatin 14darolutamide 13Radiotherapy 13Pluvicto 12Ipilimumab 12Mitomycin 11olaparib 10atezolizumab 10X-Rays 10erdafitinib 9cabazitaxel 9Radiation 9Carboplatin 9belzutifan 8Standard of Care 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
durvalumab × Genitourinary × 30 days × Clear all
NCT04960709 2026-06-04

VOLGA

AstraZeneca

Phase 3 Active not recruiting
712 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT04628767 2026-06-03

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2/3 Recruiting
131 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

NCT03682068 2026-05-28

NILE

AstraZeneca

Phase 3 Active not recruiting
1,246 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT05943106 2026-05-26

PATAPSCO

AstraZeneca

Phase 3 Active not recruiting
100 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT04216290 2026-05-22

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
11 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT05043090 2026-05-22

SAMETA

AstraZeneca

Phase 3 Active not recruiting
148 enrolled
Genitourinary

Carcinoma, Carcinoma, Renal Cell, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡